TRANZYME COMPLETES TRIAL OF TZP-101

A A

Tranzyme Pharma has successfully completed a Phase I clinical trial of its first drug candidate, TZP-101, a new chemical entity originating from the company's proprietary small molecule macrocyclic chemistry technology.

TZP-101 is a selective ghrelin receptor agonist with potent gastroprokinetic properties that represents the first in its class to enter into a clinical trial. Tranzyme Pharma is developing TZP-101 as a mechanism-based therapy for post-operative ileus (POI) and other gastrointestinal (GI) motility disorders. The study demonstrated that TZP-101 is safe and well tolerated in healthy subjects and that the safety and pharmacokinetic profile of the compound support further clinical development.